Kriya, a biopharmaceutical company developing gene therapies, completed the acquisition of Tramontane Therapeutics, a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases. Financial terms were not disclosed. "We are very impressed with the data associated with the Tramontane FGF21 program, which has consistently established strong efficacy and durability across multiple validated animal models of obesity and NASH. The addition of Tramontane’s FGF21 program strategically aligns with our Metabolic Disease portfolio which also includes a one-time gene therapy candidate for insulin-dependent diabetes," Shankar Ramaswamy, Kriya Co-Founder and CEO.